Critical Path Institute
Critical Path Institute is a nonprofit public-private partnership that convenes pharmaceutical firms, regulators, and patient groups to generate FDA/EMA-endorsed drug development tools, biomarkers, and standardized data platforms across 26 therapeutic areas, with 40+ regulatory endorsements globally.
- Company typePrivate
- Founded2005
- HeadquartersTucson, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Critical Path Institute does
Critical Path Institute (C-Path) is a US-headquartered nonprofit founded in 2005 under the FDA's Critical Path Initiative, operating as an independent public-private partnership that convenes pharmaceutical companies, regulators (FDA, EMA, PMDA), academic institutions, and patient advocacy organizations to generate drug development tools. The organization runs 26 active programs spanning neuroscience (Alzheimer's, Parkinson's, Huntington's, rare neurodegenerative diseases), rare and orphan diseases (Duchenne muscular dystrophy, polycystic kidney disease, Friedreich's ataxia, Niemann-Pick), pediatrics, tuberculosis, type 1 diabetes, and transplantation. Its core outputs are regulatory-grade drug development tools — including the first FDA/EMA-endorsed computational trial simulator for Alzheimer's disease, the first imaging biomarker qualified for polycystic kidney disease trials, and 40+ total regulatory endorsements across FDA, EMA, and PMDA, more than any other organization globally.
C-Path's technical platform comprises cloud-based data and analytics infrastructure built on CDISC SDTM standards, integrating over 700,000 standardized patient records across multiple therapeutic areas. Key products include the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), the CPP Integrated Parkinson's Database (600+ variables), TB-APEX/TB-PACTS for tuberculosis, MSOAC's placebo database (2,465 MS patient records), and the Duchenne Regulatory Science Consortium Database. Quantitative tools include clinical trial simulation platforms (Alzheimer's disease, T1D, DMD), enrichment tools (pre-dementia Alzheimer's, early motor Parkinson's DAT, islet autoantibody T1D), and the Quantitative Medicine Program implementing model-informed drug development. The organization also operates the Patient-Centered Evidence Consortium, eCOA Consortium, PSTC (Predictive Safety Testing Consortium, est. 2006), and newer initiatives including NAMs-DC (2026) and One to Millions (2026).
C-Path's revenue model combines consortium membership fees (recurring payments from pharma, biotech, and technology firms participating in collaborative programs), public-sector grants (FDA contracts, Horizon Europe, Flinn Foundation, Science Foundation Arizona), private foundation support (Michael J. Fox Foundation, Parkinson's UK), and individual donations. Pricing is not publicly disclosed; the organization operates two offices (Tucson, AZ and Amsterdam, Netherlands) with distributed European staff across Ireland, the UK, and Cyprus, serving a global client base of drug developers and regulators.
Critical Path Institute firmographics
Firmographics- Name
- Critical Path Institute
- Legal name
- Critical Path Institute
- Website
- https://c-path.org
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Critical Path Institute is a nonprofit public-private partnership that convenes pharmaceutical firms, regulators, and patient groups to generate FDA/EMA-endorsed drug development tools, biomarkers, and standardized data platforms across 26 therapeutic areas, with 40+ regulatory endorsements globally.
- Ownership category
- akta.pro rank
Critical Path Institute industry classification
Industry- Product category
- Regulatory Science and Drug Development Tools
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
- akta.pro secondary industries
- Electronic Data Capture (EDC) Platforms (HLACAOAA), Data Management, Reporting & Regulatory Submissions for Central Labs (HLAGAEAL)
Keywords
Where Critical Path Institute is headquartered
LocationHeadquarters
- HQ city
- Tucson
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Critical Path Institute business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- Donations and Grants: C-Path operates as a nonprofit organization funded through donations, grants, and public-private partnership contributions. The organization accepts donations through its website and has received grants from organizations including FDA, Science Foundation Arizona, Flinn Foundation, and others.
- Membership Fees: Consortia and coalitions such as NAMs-DC operate on membership fee structures where pharmaceutical companies, biotech companies, and other stakeholders pay to participate in collaborative development efforts.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels12 records
Critical Path Institute product offering
Product offeringCore offering
Critical Path Institute is a nonprofit organization that convenes pharmaceutical companies, biotech firms, regulators, academics, and patient advocates to co-create regulatory-grade drug development tools. It builds clinical trial simulation and enrichment tools, standardized patient-level databases, biomarker qualification packages, and electronic clinical outcome assessments that are submitted to the FDA, EMA, and PMDA for formal endorsement. The organization operates multiple consortia (including Critical Path for Parkinson's, Critical Path for Alzheimer's Disease, and the Rare Disease Clinical Outcome Assessment Consortium) and runs cloud-based data platforms such as RDCA-DAP, TB-PACTS, TB-APEX, and PAN-TB.
Product overview
Critical Path Institute is a nonprofit organization that serves as a neutral public-private partnership catalyst for accelerating drug development. The organization operates a portfolio of specialized programs, consortia, tools, and data platforms that work together to address specific unmet needs across therapeutic areas. The core offerings include: clinical trial simulation and enrichment tools (for Alzheimer's, Parkinson's, Duchenne Muscular Dystrophy, and Type 1 Diabetes); data collaboration platforms and databases (RDCA-DAP, CPAD Database, PKDOC, MSOAC, CPP Integrated Parkinson's Database, FA-ICD); clinical outcome assessment programs and resources; and regulatory science initiatives. The organization also manages a network of therapeutic-focused consortia including Critical Path for Parkinson's, Critical Path for Alzheimer's Disease, CP-RND, D-RSC, Huntington's Disease RSC, PSTC, T1D Consortium, and International Neonatal Consortium. Additional programs include the One to Millions initiative (for advanced therapies) and NAMs-DC (for new approach methodologies). C-Path was created under FDA's Critical Path Initiative in 2005 and operates from headquarters in Tucson, Arizona and Amsterdam, Netherlands. Core competencies span Data Management and Standards, Biomarkers, Modeling and Analytics, Regulatory Science, and Clinical Outcome Assessments.
Differentiator
Problem solved
Functional benefit
Products and services
- Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) Cloud-based platform promoting sharing of existing patient-level data and standardization of new data collection for rare disease research. Integrates data for analytics to accelerate understanding of disease progression, clinical outcome measures, biomarkers, and facilitates development of mathematical models and innovative clinical trial designs.
- TB-PACTS (Tuberculosis Clinical Trials Data Platform) Platform for curation and standardization of Phase III tuberculosis clinical trial data, making individual patient-level data from REMoxTB, RIFAQUIN, and OFLUTUB trials publicly available to qualified researchers.
- TB-APEX (TB Preclinical Experiments Data Platform) Platform designed to catalyze and accelerate TB research by curating and standardizing preclinical study data and making it publicly available to qualified researchers.
- PAN-TB Collaboration Platform Platform for curation and standardization of pharmacokinetic and relapsing mouse model study data, making preclinical combination studies publicly available to qualified researchers.
- Alzheimer's Pre-dementia Clinical Trial Enrichment Tool A quantitative clinical trial enrichment tool to help optimize clinical trial design in the pre-dementia stages of Alzheimer's disease, using CDR-SB as the primary endpoint. Based on a disease progression model integrating baseline hippocampal volume, patient drop-out effects, and relevant sources of variability.
- Alzheimer's Disease Clinical Trial Simulation Tool A clinical trial simulation tool to help optimize clinical trial design for mild and moderate Alzheimer's disease, using ADAS-cog as the primary cognitive endpoint. Based on a drug-disease-trial model describing disease progression, drug effects, dropout rates, placebo effect, and relevant sources of variability.
- DMD Clinical Trial Simulation Tool Developed by the Duchenne Regulatory Science Consortium (D-RSC), this tool optimizes clinical trial design of efficacy studies for potential DMD therapies by modeling longitudinal changes in functional test completion velocities.
- Early Motor Parkinson's DAT Clinical Trial Enrichment Tool A quantitative clinical trial enrichment tool to help optimize clinical trial design in the early-motor stages of Parkinson's disease, using MDS-UPDRS part III as the primary endpoint. Includes a cloud-based GUI for user-friendly simulations.
- Islet Autoantibody Clinical Trial Enrichment Tool A quantitative clinical trial enrichment tool to optimize trial design for therapies to prevent or delay T1D diagnosis, using islet autoantibodies with other relevant clinical features to increase trial power relative to unenriched trials.
- Critical Path for Alzheimer's Disease (CPAD) Database Contains demographic information, APOE4 genotype, concomitant medications, and cognitive scales (MMSE, ADAS-Cog). Includes remapped data to CDISC SDTM v3.1.2 standard.
- CPP Integrated Parkinson's Database Comprehensive collection of observational and clinical studies containing integrated and standardized data from PD observational studies and randomized clinical trials with thousands of anonymized participant records covering over 600 variables.
- Critical Path for Parkinson's (CPP) Consortium A global public-private partnership initiated in 2015 consisting of industry, nonprofit organizations, academic partners, and advisors (FDA, EMA, NIH) with the goal of accelerating approval of therapies for Parkinson's disease through drug development tools.
- Predictive Safety Testing Consortium (PSTC) Pioneering consortium formed in 2006 with pharma companies and FDA for regulatory qualification of safety biomarkers across multiple organ systems.
- PCE Consortium Measures and Licensing Platform The Patient-Centered Evidence Consortium maximizes impact of patient-centered evidence on drug development through rigorous scientific methods, standards, and multistakeholder collaboration. Provides information on available measures covering different therapeutic areas.
- Rare Disease Clinical Outcome Assessment Resource An initiative of C-Path's Rare Disease COA Consortium providing information on published COAs with potential to support efficacy endpoints in rare disease treatment trials.
- New Approach Methodologies Developer Coalition (NAMs-DC) Coalition bringing together companies developing NAMs to advance adoption, validation, and qualification of new approach methodologies including complex in vitro and in silico studies for drug discovery and development.
- One to Millions Initiative New initiative launched in 2026 to modernize how advanced therapies (antisense oligonucleotides, gene editing, RNA therapies, cell-based therapies) are developed, evaluated, and reimbursed, creating a scalable framework from individualized breakthroughs to global solutions.
- Translational Therapeutics Accelerator (TRxA) Initiative supporting academic investigators working to advance drug development projects.
- C-Path Europe European nonprofit headquarters based in Amsterdam, Netherlands pursuing complementary opportunities to bolster existing and new partnerships with European stakeholders, focusing on global regulatory science alignment.
Quantifiable outcome
- First new treatment and regimen for tuberculosis in more than 50 years
- +4 more outcomes
Companies that use Critical Path Institute
Customer profileNamed customers12 records
Segments6 records
Ideal customer profiles3 records
Critical Path Institute technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature8 records
Critical Path Institute partnerships and signals
Strategic signalPartnerships
50 partnerships are on record, tiered core and minor.
- Parkinson's UKcoreFounding partner of Critical Path for Parkinson's consortium in 2015. Provided generous support to establish the global public-private partnership focused on accelerating the path to approval of therapies for Parkinson's disease.
- AbbViecoreMember of Critical Path for Parkinson's consortium contributing to drug development tool creation.
- BayercoreMember of Critical Path for Parkinson's consortium.
- BiogencoreMember of Critical Path for Parkinson's consortium.
- NovartiscoreMember of Critical Path for Parkinson's consortium.
- F. Hoffmann-LaRoche Ltd.coreMember of Critical Path for Parkinson's consortium.
- Sanofi GenzymecoreMember of Critical Path for Parkinson's consortium.
- UCBcoreMember of Critical Path for Parkinson's consortium.
- The Michael J. Fox Foundation for Parkinson's ResearchcoreNonprofit organization collaborating on Parkinson's research within the CPP consortium.
- European Medicines Agency (EMA)coreRegulatory agency partner providing guidance and endorsement of drug development tools. Has issued qualification opinions, letters of support, and endorsements for C-Path developed tools.
- U.S. Food and Drug Administration (FDA)corePrimary regulatory partner operating under a formal Memorandum of Understanding. FDA partners with C-Path to materialize the FDA's Critical Path Initiative mission.
- World Health Organization (WHO)coreSelected C-Path to host TB clinical trials data. C-Path participates in WHO GAP-f project for pediatric formulations.
- Innovative Health Initiative (IHI)coreC-Path collaborates on projects funded under IMI JU2 within the AMR Accelerator programme for tuberculosis treatment development.
- Horizon EuropecoreEuropean funding programme supporting C-Path's participation in ERDERA and More-EUROPA projects.
- European Joint Programme on Rare Diseases (EJPRD)coreC-Path partners in this EU programme focused on rare disease research coordination.
- EMA Regulatory Science StrategycoreC-Path engages with EMA's Regulatory Science Research Needs initiative.
- Newcastle UniversitycoreAcademic institution collaborating as part of Critical Path for Parkinson's consortium.
- Radboud UniversitycoreAcademic institution collaborating on Parkinson's research.
- University of CambridgecoreAcademic partner in Critical Path for Parkinson's consortium.
- University of OxfordcoreAcademic partner in Critical Path for Parkinson's consortium.
- UNITE4TB PartnershipcoreAcademia and Industry United Innovation and Treatment for Tuberculosis project, a public-private initiative C-Path participates in as work package lead for data management.
- ERA4TBcoreEuropean Regimen Accelerator for Tuberculosis project with over 30 organizations developing drugs against TB. C-Path leads data and pipeline management.
- PAN-TB CollaborationcoreProject to Accelerate New Treatments for Tuberculosis leveraging collective resources to identify and evaluate new drug regimens.
- Rare Disease MoonshotcoreCoalition promoting integration of regulatory science in rare disease public-private partnerships.
- ERDERAcoreEuropean Rare Disease Research Alliance funded through Horizon Europe.
- More-EUROPAcoreProject supporting efficient use of real-world data in medicinal product development in Europe.
- CN BiocoreMember of NAMs-DC coalition developing new approach methodologies for drug discovery.
- Crown BiosciencecoreMember of NAMs-DC coalition. Joined in July 2026.
- EmulatecoreMember of NAMs-DC coalition developing organ-on-a-chip and other human-relevant testing methods.
- InSpherocoreMember of NAMs-DC coalition developing 3D cell models and liver disease models.
- Curi BiocoreMember of NAMs-DC coalition.
- ModeluscoreMember of NAMs-DC coalition.
- Revalia BiocoreMember of NAMs-DC coalition.
- VivoSpherecoreMember of NAMs-DC coalition.
- Movement Disorders SocietycoreNonprofit organization collaborating as part of Critical Path for Parkinson's.
- Parkinson's FoundationcoreNonprofit organization supporting Parkinson's research and patient care.
- Davis Phinney FoundationcoreNonprofit organization focused on Parkinson's research and quality of life.
- Parkinson's EuropecoreEuropean Parkinson's patient advocacy organization.
- National Institute of Neurologic Diseases and Stroke (NINDS)coreU.S. government agency supporting neurological research.
- University of ArizonacoreFounding partner and academic institution. C-Path established under auspices of FDA's Critical Path Initiative with support from University of Arizona. Hosts graduate certificate program in regulatory science.
- Annovis BiominorMember of Critical Path for Parkinson's consortium.
- AskBiominorMember of Critical Path for Parkinson's consortium.
- BiohavenminorMember of Critical Path for Parkinson's consortium.
- BlueRock TherapeuticsminorMember of Critical Path for Parkinson's consortium.
- CLARIOminorMember of Critical Path for Parkinson's consortium.
- IXICOminorMember of Critical Path for Parkinson's consortium.
- Merck Sharp and Dohme (MSD)minorMember of Critical Path for Parkinson's consortium.
- Neuron23minorMember of Critical Path for Parkinson's consortium.
- Octave BioScienceminorMember of Critical Path for Parkinson's consortium.
- Vanqua BiominorMember of Critical Path for Parkinson's consortium.
Scale indicators10 records
Recent moves8 records
Expansion highlights6 records
Critical Path Institute competitors and assessment
Company assessmentDirect peers
- TransCelerate BioPharma: Precompetitive pharma-funded collaboration solving common drug development challenges (clinical data standards, protocol design, safety). Most direct peer — same consortium model, overlapping pharma member base, and competing for the same precompetitive convener role.
- Foundation for the National Institutes of Health (FNIH): 501(c)(3) nonprofit that convenes NIH, FDA, industry, and academia around precompetitive biomedical partnerships (e.g., AMP, Biomarkers Consortium). Closest functional analog as a neutral public-private partnership catalyst.
- Reagan-Udall Foundation for the FDA: Independent nonprofit created by Congress to support FDA's regulatory science mission through public-private collaboration. Closest peer in mission (regulatory science advancement) and structural form (FDA-affiliated nonprofit).
- Innovative Health Initiative (IHI): EU public-private partnership (successor to IMI) funding cross-sector health research consortia. Direct peer in Europe — C-Path participates in IHI projects as a partner.
- Clinical Data Interchange Standards Consortium (CDISC): Standards organization developing CDISC SDTM data standards used in clinical research — C-Path applies CDISC standards in its data platforms and co-launched the CFAST initiative with CDISC. Tightly coupled technical peer.
Broad incumbents
- IQVIA: Largest global CRO and clinical trial technology vendor offering trial design, EDC, and real-world data at commercial scale. Overlaps C-Path's data and trial-simulation functions but as a broad, for-profit portfolio rather than a neutral nonprofit specialist.
- Parexel: Global CRO providing clinical trial design, modeling & simulation, and regulatory consulting. Comparable in trial-simulation and regulatory-science offerings; competes for the same pharma services wallet.
Others
- Bill & Melinda Gates Foundation: Large philanthropic funder that has historically supported precompetitive global-health R&D (TB, malaria, vaccines). Adjacent funder/ecosystem peer rather than direct competitor — overlaps in TB and global health agendas.
- EFGCP (European Forum for Good Clinical Practice): European nonprofit working on GCP, regulatory science, and trial methodology best practices. Adjacent ecosystem peer focused on European regulatory practice standards.
- BIO (Biotechnology Innovation Organization): Largest US biotech trade association. While not a direct service provider, BIO convenes industry voices on regulatory policy in a manner analogous to C-Path's precompetitive-consortium role.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Critical Path Institute social profiles
Digital presenceCritical Path Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
Critical Path Institute leadership team
Management profileNumber of profiles
Profiles10 records
Critical Path Institute subsidiaries and ownership
Company hierarchySubsidiaries1 record
Critical Path Institute funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Critical Path Institute M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Critical Path Institute
What does Critical Path Institute do?
Critical Path Institute is a nonprofit organization that convenes pharmaceutical companies, biotech firms, regulators, academics, and patient advocates to co-create regulatory-grade drug development tools. It builds clinical trial simulation and enrichment tools, standardized patient-level databases, biomarker qualification packages, and electronic clinical outcome assessments that are submitted to the FDA, EMA, and PMDA for formal endorsement. The organization operates multiple consortia (including Critical Path for Parkinson's, Critical Path for Alzheimer's Disease, and the Rare Disease Clinical Outcome Assessment Consortium) and runs cloud-based data platforms such as RDCA-DAP, TB-PACTS, TB-APEX, and PAN-TB.
Is Critical Path Institute a public or private company?
Critical Path Institute is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Critical Path Institute founded?
Critical Path Institute was founded in 2005. It employs 11 to 50 people.
Where is Critical Path Institute based?
Critical Path Institute is headquartered in Tucson, United States, in the North America region.
How does Critical Path Institute make money?
Two revenue lines are on record. Donations and Grants are the primary driver. The others are membership Fees.
Who are Critical Path Institute's main competitors?
Direct peers on record are TransCelerate BioPharma, Foundation for the National Institutes of Health (FNIH), Reagan-Udall Foundation for the FDA, Innovative Health Initiative (IHI) and Clinical Data Interchange Standards Consortium (CDISC). Broad incumbents are IQVIA and Parexel. Others are Bill & Melinda Gates Foundation, EFGCP (European Forum for Good Clinical Practice) and BIO (Biotechnology Innovation Organization).
Does Critical Path Institute have an API?
No public API is recorded for Critical Path Institute.
What industry is Critical Path Institute in?
Critical Path Institute's product category is Regulatory Science and Drug Development Tools. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF), with a secondary code of HLACAOAA, Electronic Data Capture (EDC) Platforms. Its NAICS code is 54169 and its SIC code is 8731.